ScienHub Research Support contributes to the development of HIPRA’s COVID-19 vaccine in the EU

ScienHub Research Support has played a key role in the clinical trials for the development of HIPRA’s vaccine, the first recombinant protein bivalent COVID-19 vaccine authorized in the European Union, ScienHub CTU has coordinated the implementation of the trials at the Germans Trias i Pujol Hospital site and has been the CRO responsable for the monitoring of one of HIPRA’s trials (RBDCOV project).

0
    0
    Your Cart
    Your cart is emptyReturn to Shop